Tìm theo
Quinupristin
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 120138-50-3
ĐG : DSM Corp. , http://www.dsm.com
CTHH: C53H67N9O10S
PTK: 1022.218
Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C53H67N9O10S
Phân tử khối
1022.218
Monoisotopic mass
1021.473160099
InChI
InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35?,37-,38+,39?,40+,43-,44+,45+/m1/s1
InChI Key
InChIKey=WTHRRGMBUAHGNI-MJWHERSYSA-N
IUPAC Name
N-[(3S,6S,12R,15S,16R,19S)-25-{[(3S)-1-azabicyclo[2.2.2]octan-3-ylsulfanyl]methyl}-3-{[4-(dimethylamino)phenyl]methyl}-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentaazatricyclo[20.4.0.0^{6,10}]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
Traditional IUPAC Name
N-[(3S,6S,12R,15S,16R,19S)-25-{[(3S)-1-azabicyclo[2.2.2]octan-3-ylsulfanyl]methyl}-3-{[4-(dimethylamino)phenyl]methyl}-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentaazatricyclo[20.4.0.0^{6,10}]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
SMILES
CC[C@H]1NC(=O)[C@@H](NC(=O)C2=NC=CC=C2O)[C@@H](C)OC(=O)[C@@H](NC(=O)C2CC(=O)C(CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](CC2=CC=C(C=C2)N(C)C)N(C)C(=O)[C@@H]2CCCN2C1=O)C1=CC=CC=C1
Độ hòa tan
4.45e-02 g/l
logP
2.18
logS
-4.4
pKa (strongest acidic)
7.45
pKa (Strongest Basic)
8.28
PSA
231.2 Å2
Refractivity
272.84 m3·mol-1
Polarizability
107.02 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
12
H Bond Donor Count
4
Physiological Charge
1
Number of Rings
8
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Quinupristin is a streptogramin antibiotic, derived from pristinamycin I. By inhibiting the bacterial ribosomal subunits, protein synthesis is inhibited thus leading to eventual bacterial cell death or stasis.
Cơ Chế Tác Dụng : Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone. Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome. Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation it, enhancing the binding of quinupristin by a factor of about 100. In addition, it inhibits peptidyl transferase. Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released.
Dược Động Học :

▧ Protein binding :
Moderate.
▧ Metabolism :
Quinupristin is converted to two conjugated active major metabolites, one with glutathione and one with cysteine.
▧ Half Life :
3.1 hours
Chỉ Định : For the treatment of bacterial infections (usually in combination with dalfopristin).
Tương Tác Thuốc :
  • Amlodipine This combination presents an increased risk of toxicity
  • Arsenic trioxide This combination presents an increased risk of toxicity
  • Astemizole This combination presents an increased risk of toxicity
  • Atorvastatin This combination presents an increased risk of toxicity
  • Carbamazepine This combination presents an increased risk of toxicity
  • Cerivastatin This combination presents an increased risk of toxicity
  • Cisapride This combination presents an increased risk of toxicity
  • Clarithromycin This combination presents an increased risk of toxicity
  • Cyclosporine Synercid increases the effect of cyclosporine
  • Delavirdine This combination presents an increased risk of toxicity
  • Diazepam This combination presents an increased risk of toxicity
  • Dihydroquinidine barbiturate This combination presents an increased risk of toxicity
  • Diltiazem This combination presents an increased risk of toxicity
  • Disopyramide This combination presents an increased risk of toxicity
  • Docetaxel This combination presents an increased risk of toxicity.
  • Dofetilide This combination presents an increased risk of toxicity
  • Droperidol This combination presents an increased risk of toxicity
  • Erythromycin This combination presents an increased risk of toxicity
  • Etoposide This combination presents an increased risk of toxicity
  • Felbamate This combination presents an increased risk of toxicity
  • Felodipine This combination presents an increased risk of toxicity
  • Flecainide This combination presents an increased risk of toxicity
  • Foscarnet This combination presents an increased risk of toxicity
  • Fosphenytoin This combination presents an increased risk of toxicity
  • Gatifloxacin This combination presents an increased risk of toxicity
  • Grepafloxacin This combination presents an increased risk of toxicity
  • Halofantrine This combination presents an increased risk of toxicity
  • Indinavir This combination presents an increased risk of toxicity
  • Isradipine This combination presents an increased risk of toxicity
  • Lercanidipine This combination presents an increased risk of toxicity
  • Levofloxacin This combination presents an increased risk of toxicity
  • Levomethadyl Acetate This combination presents an increased risk of toxicity
  • Lidocaine This combination presents an increased risk of toxicity
  • Losartan This combination presents an increased risk of toxicity
  • Lovastatin This combination presents an increased risk of toxicity
  • Methylprednisolone This combination presents an increased risk of toxicity
  • Midazolam This combination presents an increased risk of toxicity
  • Moexipril This combination presents an increased risk of toxicity
  • Moxifloxacin This combination presents an increased risk of toxicity
  • Nevirapine This combination presents an increased risk of toxicity
  • Nicardipine This combination presents an increased risk of toxicity
  • Nifedipine Synercid increases the effect of ziprasidone
  • Nimodipine This combination presents an increased risk of toxicity
  • Nisoldipine This combination presents an increased risk of toxicity
  • Octreotide This combination presents an increased risk of toxicity
  • Paclitaxel This combination presents an increased risk of toxicity
  • Pentamidine This combination presents an increased risk of toxicity
  • Quetiapine This combination presents an increased risk of toxicity
  • Quinidine This combination presents an increased risk of toxicity
  • Quinidine barbiturate This combination presents an increased risk of toxicity
  • Ritonavir This combination presents an increased risk of toxicity
  • Salmeterol This combination presents an increased risk of toxicity
  • Simvastatin This combination presents an increased risk of toxicity
  • Tacrolimus This combination presents an increased risk of toxicity
  • Tamoxifen This combination presents an increased risk of toxicity
  • Teniposide This combination presents an increased risk of toxicity
  • Terfenadine This combination presents an increased risk of toxicity
  • Tizanidine This combination presents an increased risk of toxicity
  • Venlafaxine This combination presents an increased risk of toxicity
  • Verapamil This combination presents an increased risk of toxicity
  • Vinblastine This combination presents an increased risk of toxicity
  • Vincristine This combination presents an increased risk of toxicity
  • Vindesine This combination presents an increased risk of toxicity
  • Vinorelbine This combination presents an increased risk of toxicity
Dữ Kiện Thương Mại
... loading
... loading